Recombinant Human UDP-glucuronosyltransferase 2B17 (UGT2B17)

What is UDP-glucuronosyltransferase 2B17 and what is its primary biological function?

UDP-glucuronosyltransferase 2B17 (UGT2B17) belongs to the UGT family of enzymes that catalyze the conjugation of glucuronic acid to various substrates. This glucuronidation process increases the hydrophilicity of compounds, alters their biological activity, and facilitates their excretion through urine and bile . UGT2B17 has been identified as the major enzyme responsible for testosterone glucuronidation, while UGT2B15 plays a comparatively minor role in this process .

The primary function of UGT2B17 is to facilitate the detoxification and elimination of both endogenous compounds (particularly androgens) and xenobiotics from the body. This enzyme catalyzes glucuronidation at multiple hydroxyl positions, making it particularly efficient in steroid metabolism compared to other UGT enzymes that may have more restricted site specificity .

Where is UGT2B17 expressed in human tissues?

UGT2B17 demonstrates a tissue-specific expression pattern that influences its metabolic impact. While UGT enzymes including UGT2B17 are predominantly expressed in the liver (the primary site of drug metabolism), they are also found in various extrahepatic tissues including the kidney, gastrointestinal tract, lungs, prostate, mammary glands, skin, brain, spleen, and nasal mucosa .

This widespread distribution explains why UGT2B17 impacts not only systemic drug metabolism but also local tissue-specific metabolism. The expression in organs like the prostate is particularly relevant to its role in androgen metabolism and potential implications for prostate cancer risk .

How does UGT2B17 differ from other UGT enzymes in substrate specificity?

UGT2B17 demonstrates distinct substrate specificity compared to other UGT enzymes, particularly in relation to steroid metabolism. Unlike UGT2B15 which acts only at the 17β-OH position of steroids, UGT2B17 catalyzes glucuronidation at multiple hydroxyl positions, making it more efficient in steroid elimination .

In enzyme kinetic studies, UGT2B17 has shown remarkably high affinity for certain substrates. For example, with the compound MK-7246, recombinant UGT2B17 exhibited a Km value of 3.2 μmol/l, which was 25-30 fold lower than other UGT enzymes (indicating much higher affinity) . This high substrate affinity was comparable to human intestinal microsomes and significantly better than other recombinant UGTs tested .

What are the known genetic polymorphisms of UGT2B17 and their functional consequences?

The most significant polymorphism identified in the UGT2B17 gene is a deletion polymorphism, which can result in complete absence of the UGT2B17 enzyme in individuals homozygous for the deletion (del/del genotype) . This polymorphism has profound functional consequences for steroid metabolism and drug pharmacokinetics.

The deletion polymorphism in UGT2B17 results in reduced glucuronidation capacity for various substrates, particularly androgens like testosterone. This reduction in metabolic capacity leads to altered pharmacokinetics of drugs that are substrates for UGT2B17. For example, individuals with the UGT2B17*2/2 genotype (homozygous deletion) show dramatically higher systemic exposure to certain drugs compared to those with the UGT2B171/*1 wild-type genotype .

How can researchers detect and characterize UGT2B17 polymorphisms in study populations?

For accurate genotyping of UGT2B17 polymorphisms, real-time PCR with allelic discrimination is the recommended method . This technique enables researchers to distinguish between the three possible genotypes: homozygous wild-type (ins/ins), heterozygous (ins/del), and homozygous deletion (del/del) .

A comprehensive approach to characterizing UGT2B17 polymorphisms in research populations should include:

• DNA extraction from appropriate biological samples (blood, saliva, or tissue)

• Real-time PCR with specific primers designed to detect the UGT2B17 deletion

• Allelic discrimination analysis to determine genotype

• Validation of results using positive and negative controls

• Statistical analysis of genotype distributions in the studied population

When conducting population studies, researchers should account for potential ethnic differences in the frequency of UGT2B17 deletion, as considerable inter-ethnic variations have been reported .

How does UGT2B17 genetic variation affect drug pharmacokinetics?

UGT2B17 genetic polymorphisms can dramatically alter the pharmacokinetics of drugs that are substrates for this enzyme. The impact is particularly significant for individuals with the homozygous deletion genotype (UGT2B17*2/*2).

In clinical studies with the compound MK-7246, subjects with the UGT2B17*2/*2 genotype exhibited:

• 25-fold greater mean dose-normalized area under the plasma concentration-time curve (AUC)

• 82-fold greater peak concentration (Cmax)

• 24-fold lower metabolite-to-parent drug AUC ratio

compared to subjects with the UGT2B17*1/*1 wild-type genotype .

These findings demonstrate that UGT2B17 deficiency can lead to dramatically increased drug exposure, potentially requiring dose adjustments or alternative treatments for affected individuals .

What alternative metabolic pathways exist for compounds typically metabolized by UGT2B17?

In individuals with deficient UGT2B17 function, several potential compensatory pathways might be engaged, though with varying efficiency:

• Other UGT enzymes: UGT1A1, 1A3, 1A4, 1A8, 1A9, 1A10, 2B4, 2B7, and 2B15 may contribute to steroid glucuronidation, but with significantly lower efficiency than UGT2B17 .

• Sulphation pathways: Research has shown that individuals with del/del UGT2B17 genotypes do not produce significantly increased amounts of steroid sulphate conjugates, suggesting that sulphation is not effectively upregulated as a compensatory mechanism .

• Alternative elimination routes: In the absence of efficient glucuronidation, lipophilic unconjugated steroids may:

  • Distribute into body tissues

  • Incorporate into hair via endogenous routes

  • Excrete in sweat

  • Undergo minor direct urinary excretion as unconjugated compounds

The inadequacy of these alternative pathways explains the substantially altered pharmacokinetics observed in UGT2B17-deficient individuals and highlights the importance of considering genetic polymorphisms in drug development and dosing strategies.

What are the optimal methods for studying UGT2B17 enzyme kinetics?

For rigorous characterization of UGT2B17 enzyme kinetics, researchers should employ a multi-system approach comparing recombinant enzymes with human tissue microsomes. Based on published methodologies, the following approach is recommended:

• Enzyme sources preparation:

  • Recombinant UGT2B17 expressed in suitable systems (e.g., baculovirus-infected insect cells)

  • Human liver microsomes (HLMs) from donors with known UGT2B17 genotypes

  • Human intestinal microsomes (HIMs) to assess extrahepatic metabolism

• Kinetic analysis methodology:

  • Incubate substrate at varying concentrations with enzyme sources in the presence of UDP-glucuronic acid (UDPGA)

  • Measure reaction products using LC-MS/MS or other suitable analytical techniques

  • Plot substrate concentration versus reaction velocity to determine reaction kinetics

  • Calculate kinetic parameters (Km, Vmax) using appropriate software

• Comparative analysis:

  • Compare kinetic parameters across different enzyme sources

  • Determine the relative contribution of UGT2B17 to total glucuronidation activity

This approach has successfully identified UGT2B17 as the major UGT enzyme for various substrates, showing its distinct kinetic properties compared to other UGT enzymes .

How can researchers effectively investigate the impact of UGT2B17 polymorphisms on drug metabolism?

To comprehensively investigate the impact of UGT2B17 polymorphisms on drug metabolism, a three-component research strategy is recommended:

• Single-dose pharmacokinetic studies:

  • Administer labeled compounds to healthy volunteers with different UGT2B17 genotypes

  • Conduct comprehensive sample collection (blood, urine, hair, sweat)

  • Perform detailed pharmacokinetic analysis to determine differences in drug disposition

  • Quantify parent compounds and metabolites to assess metabolic pathways

• Animal model studies:

  • Develop animal models with different UGT2B17 genotypes

  • Perform controlled comparative pharmacokinetic studies with acute and chronic drug administration

  • Monitor physiological parameters to assess potential toxicity

  • Compare animal data with human single-dose studies

• Clinical genotype-phenotype correlation studies:

  • Analyze UGT2B17 genotypes in patients showing abnormal drug responses

  • Correlate genotypes with clinical outcomes and adverse events

  • Assess the prevalence of different UGT2B17 genotypes in patient populations

  • Evaluate the clinical significance of observed pharmacokinetic differences

This comprehensive approach allows researchers to establish causal relationships between UGT2B17 polymorphisms and clinically relevant pharmacokinetic variations.

What is the proposed connection between UGT2B17 gene deletion and renal disorders in anabolic steroid users?

A compelling hypothesis connects UGT2B17 gene deletion with increased risk of renal disorders in individuals using anabolic androgenic steroids (AAS) . The proposed mechanism involves several interconnected pathways:

• Impaired steroid elimination: UGT2B17 deficiency leads to reduced glucuronidation and elimination of anabolic steroids.

• Elevated circulating steroids: Due to impaired elimination, biologically active steroids remain in circulation longer and at higher concentrations.

• Increased body mass: Prolonged exposure to elevated steroid levels enhances muscle build-up, increasing body mass index.

• Renal impact: The combination of increased body mass (causing elevated glomerular pressure and flow rate) and potential direct toxic effects of steroids on kidney tissues may lead to renal injury over time .

This hypothesis suggests that individuals with UGT2B17 gene deletion who use anabolic steroids long-term may represent a high-risk population for developing renal complications. The hypothesis has significant implications for personalized risk assessment in both therapeutic steroid use and anti-doping contexts .

How might UGT2B17 polymorphisms influence prostate cancer risk?

The relationship between UGT2B17 polymorphisms and prostate cancer risk represents an active area of research with complex and sometimes conflicting evidence . Several mechanistic pathways have been proposed:

• Androgen metabolism alteration: Since UGT2B17 is the major enzyme for testosterone glucuronidation, its deletion polymorphism results in reduced testosterone elimination and potentially increased androgen exposure in prostate tissue.

• Steroid hormone balance: Impaired glucuronidation may alter the balance of active androgens in the prostate, potentially influencing cellular growth and differentiation pathways associated with cancer development.

• Environmental interactions: UGT2B17 polymorphisms might interact with environmental factors, including dietary components or medications that inhibit UGT enzymes.

Despite these plausible mechanisms, clinical studies have produced both positive and negative outcomes regarding the association between UGT2B17 deletion and prostate cancer risk . This inconsistency suggests that the relationship is complex and likely involves interactions with other genetic and environmental factors. Future research should focus on large-scale, well-controlled studies that account for these potential interactions.

What compounds are known to inhibit UGT2B17 and how might this affect endogenous and exogenous substrate metabolism?

Several compounds have been identified as inhibitors of UGT2B17 enzyme activity, with potential implications for both endogenous hormone metabolism and drug interactions:

• Non-steroidal anti-inflammatory drugs (NSAIDs):

  • Diclofenac and ibuprofen have demonstrated inhibitory effects on testosterone glucuronidation

  • This inhibition could potentially increase circulating testosterone levels

• Dietary components:

  • Tea extracts contain compounds that inhibit UGT2B17 activity

  • Red wine extracts have shown inhibitory effects on testosterone glucuronidation

• Potential consequences of inhibition:

  • Increased levels of circulating testosterone and other androgens

  • Altered pharmacokinetics of drugs metabolized by UGT2B17

  • Potential exacerbation of prostate cancer risk in susceptible individuals

The inhibition of UGT2B17 by commonly consumed substances raises important considerations for drug-drug and food-drug interactions. For researchers designing clinical studies involving UGT2B17 substrates, careful consideration should be given to controlling for these potential inhibitory effects through dietary restrictions or medication reconciliation.

What are the most promising areas for future UGT2B17 research?

Based on current knowledge and unresolved questions, several high-priority research directions emerge:

• Comprehensive characterization of substrate specificity:

  • Systematic evaluation of UGT2B17 activity across diverse chemical classes

  • Development of specific probe substrates for UGT2B17 activity assessment

  • Structural biology studies to understand substrate binding mechanisms

• Expanded understanding of polymorphism consequences:

  • Investigation of UGT2B17 polymorphisms across diverse ethnic populations

  • Assessment of long-term health implications of UGT2B17 deficiency

  • Development of predictive models for personalizing drug therapy based on UGT2B17 genotype

• Exploration of regulatory mechanisms:

  • Investigation of factors controlling UGT2B17 expression

  • Assessment of potential epigenetic regulation of UGT2B17

  • Evaluation of tissue-specific expression patterns and their implications

• Clinical translation:

  • Development of clinical guidelines for drugs primarily metabolized by UGT2B17

  • Assessment of genotype-guided dosing strategies for affected medications

  • Evaluation of UGT2B17 genotyping as a component of personalized medicine approaches

These research directions would address significant knowledge gaps and potentially lead to improved therapeutic strategies and personalized medicine approaches.